April 18, 2026

Top News
Lilly's Tirzepatide Risks Greater Muscle Loss vs Semaglutide; Cochrane Challenges Alzheimer's Drugs
Policy & Regulation
Optimism for Trump’s CDC pick is tempered by questions about RFK Jr.’s role

The nomination of a CDC director with scientific credentials and no ties to the anti-vaccine movement has generated guarded optimism among public health professionals despite concerns regarding RFK Jr.'s influence.

Clinical Pearl
Opinion: The podcast bringing together MAHA and public health for hard conversations

This podcast summary highlights the clinical value of engaging in respectful, non-confrontational dialogue with anti-vaccine and MAHA supporters to maintain therapeutic rapport despite unchanged convictions.

Policy & Regulation
RevMed’s stunning success; FDA to reclassify peptides; and more

The article highlights Johnson & Johnson's strategic positioning against biosimilar competition during Q1 earnings season alongside regulatory updates on peptide reclassification by the FDA.

Drug Development
GLP-1 receptor agonists and risk of suicide or suicide attempts – A nationwide cohort and self-controlled case series study

This nationwide study evaluates the association between GLP-1 receptor agonist use and the risk of suicide or suicide attempts, providing critical safety data for psychiatric prescribing decisions.

Drug Development
Cannabidiol at the crossroads: panacea, placebo, or problem?

Clinicians must critically evaluate cannabidiol's therapeutic efficacy against its potential as a placebo or source of adverse effects given current evidence limitations.

Clinical Pearls

Bite-sized clinical takeaways from today's literature (sources from Apr 15 – Apr 18)

  • Monitor patients on tirzepatide closely for lean muscle mass loss despite its superior weight reduction compared to semaglutide.
  • Consider the emerging evidence from Cochrane reviews challenging the clinical efficacy of anti-amyloid antibodies for Alzheimer's disease when discussing treatment options.
  • Leverage Lilly's obesity medication data showing cardiovascular safety in diabetic patients to support expanded prescribing indications where appropriate.
  • Evaluate GIP/glucagon receptor agonists as potential alternatives to GLP-1 agonists for patients who experience significant gastrointestinal side effects.
  • Initiate high-dose folic acid supplementation prior to conception for women with epilepsy taking antiseizure medications to reduce birth defect risks by 45%.
  • Implement robust external monitoring systems for AI-driven mental health tools, as independent safety architectures significantly outperform native model safeguards in detecting suicidal ideation.
  • Screen patients with treatment-resistant depression for CYP2C19 metabolizer status and address social support deficits alongside medication optimization.
  • Assess cannabis potency levels carefully given the rising prevalence of high-potency products and their association with severe psychiatric adverse events.
  • Incorporate findings on functional neurological disorders regarding maladaptive self-referential circuits when explaining the link between threat sensitivity and motor inhibition to patients.
  • Utilize multidimensional outcome profiling including education, employment, and hepatic status to predict long-term abstinence versus relapse in alcohol dependence treatment planning.

Policy & Regulation 3

New CDC pick Schwartz is praised by public health pros

The appointment of Erica Schwartz as CDC director aims to stabilize the agency's leadership following a period of significant operational instability, which is critical for maintaining consistent public health guidance and clinical protocols.

The deadly consequences of ICE detention

The provided text does not contain clinical information, as it is a promotional teaser for an external article regarding ICE detention deaths rather than a substantive medical report.

5 notable pharma CEO pay hikes in 2025

This article details significant compensation increases for pharmaceutical CEOs in 2025, highlighting a trend toward executive pay exceeding $30 million, which has no direct clinical or therapeutic implications for psychiatric practice.

Drug Development 3

UCB, betting on seizure cell therapy, to buy Neurona for up to $1.2B

UCB's potential $1.2B acquisition of Neurona diversifies its epilepsy portfolio by targeting a difficult-to-treat seizure form with an early-stage cell therapy.

STAT+: A pancreatic cancer expert on why Revolution Medicines’ study could ‘open up a new era’ of treatment

[OUT OF SCOPE] This article discusses a Phase 3 clinical trial for daraxonrasib in pancreatic cancer, which is outside the scope of psychiatric pharmacology and treatment.

#AACR26 preview: Revolution Medicines, the RAS bonanza and China ADC standouts

[OUT OF SCOPE] This article discusses a pan-RAS inhibitor for pancreatic cancer, which is outside the scope of psychiatric pharmacology and treatment.

Neuroscience 5

Cortisol Kill-Switch: Exercise Rewires Stress Biology

[OUT OF SCOPE] This article discusses the physiological effects of exercise on cortisol and brain aging without addressing psychiatric pharmacology, drug development, or specific psychiatric treatments.

New Blueprint for Brain Repair

Research in zebra finches reveals that newly generated neurons can displace existing circuits, suggesting a potential evolutionary trade-off where limited neurogenesis in humans protects established memories from disruption.

Noise is the Signal: Why Weak Brain Connections Predict Behavior

Weak neural connections previously dismissed as noise can predict behavior with accuracy comparable to strong signals, suggesting that analyzing this 'hidden iceberg' of brain activity offers critical new insights for understanding psychiatric disorders.

Hippocampal and Midbrain Function in Superagers Relates to Memory for Novelty and Expectation Violation

Superagers exhibit superior episodic memory through enhanced hippocampal responses to expectation violations and preserved midbrain habituation, indicating that adaptive processing of prediction errors distinguishes exceptional from typical cognitive aging.

Interoceptive dysfunction and its neural correlates in schizophrenia: protocol for a cross-sectional multimodal MRI study

This protocol outlines a multimodal MRI study designed to characterize the neural mechanisms of interoceptive dysfunction in schizophrenia, aiming to link deficits in bodily self-awareness to specific circuit abnormalities for future therapeutic development.

Digital Health 5

AI Restores Voices Through Microscopic Neck Movements

[OUT OF SCOPE] This article describes a non-pharmacological assistive technology for voice restoration in patients without vocal cords and does not address psychiatric pharmacology or treatment.

Music Corrects the Brain’s “Glitched” Predictions

[OUT OF SCOPE] This article describes a behavioral intervention (group songwriting) for psychosis rather than providing information on psychiatric pharmacology, drug development, or prescribing guidelines.

The Artemis II mission provides critical insights into the psychological resilience, crew dynamics, and stress management strategies required for long-duration deep-space psychiatric care.

Robust MR-AIV: A Systematic Study of Robustness Improvement and Sensitivity Analysis of MR-AIV

This study validates the robustness of MR-AIV, a physics-informed AI framework for non-invasive quantification of cerebrospinal fluid dynamics, by establishing stable operating regimes and practical guidelines for mapping brain-wide porous fluid transport in neurological disease research.

Towards patient-specific biomechanical human brain models

This study establishes a pipeline deriving voxel-level brain tissue stiffness from routine diffusion tensor MRI, demonstrating that accounting for local microstructural heterogeneity significantly alters predicted regional deformation patterns compared to standard region-wise models.

Podcast Summary 1

This podcast features Dr. Marlene P. Freeman discussing evidence-based strategies for managing depression with SSRIs during pregnancy to balance maternal mental health benefits against potential fetal risks.

Journal Article 3

Kailera IPO interview: CEO Renaud talks biotech market, China and obesity pipeline

Kailera IPO interview: CEO Renaud talks biotech market, China and obesity pipeline

The provided text contains only a title and lacks the necessary clinical content to extract a specific psychiatric takeaway.

The provided text contains only a title and lacks clinical data, making it impossible to extract a specific psychiatric takeaway or determine its relevance.

Diagnosis & Treatment 5

Clinicians should proactively monitor for and implement evidence-based strategies to mitigate lithium-associated weight gain, a common adverse effect impacting long-term medication adherence.

Decoding the Shame Associated with Ozempic Weight Loss

Clinicians must proactively address the unique stigma and shame patients experience when using GLP-1 agonists for weight loss, as these medications are often unfairly perceived as 'shortcuts' compared to lifestyle interventions.

This article highlights the growing clinical importance of integrating psychiatric care into dermatology to address the significant bidirectional relationship between skin conditions and mental health disorders.

Paragangliomas arising in the Organ of Zuckerkandl are rare extra-adrenal pheochromocytomas that require high clinical suspicion for diagnosis and surgical management to prevent life-threatening catecholamine crises.

Could Alzheimer’s Begin in the Nerves, Not the Brain?

Emerging evidence from human-on-a-chip models suggests Alzheimer's pathology may originate in the peripheral nervous system, indicating that motor symptoms could serve as critical early diagnostic markers before central brain involvement becomes apparent.

Mechanism of Action 5

Multiscale Mechanisms of Human Memory Modulation by Deep Brain Stimulation

Deep brain stimulation targeting hippocampal white matter at 50 Hz enhances memory while gray matter stimulation at 5 Hz impairs it, driven by distinct region-specific theta modulation and global fidelity mechanisms that enable state-dependent therapeutic precision.

Fronto-Temporal Dysconnectivity and Cortical Excitability in High Schizotypy: Associations with Symptom Dimensions

High schizotypy exhibits reduced frontal-to-temporal top-down connectivity and compensatory cortical disinhibition, mirroring mechanisms in schizophrenia and offering a biomarker for psychosis risk.

Psilocybin reshapes cortical inhibition through selective interneuron recruitment

Psilocybin modulates cortical inhibition by selectively suppressing somatostatin-expressing interneurons via 5-HT1A receptors while enhancing parvalbumin-expressing interneuron activity, revealing a critical cell-type-specific mechanism underlying its therapeutic effects.

Ceruloplasmin deficiency drives a fusiform-centric lipid–myelin pathology underlying a visual subtype in autism

Ceruloplasmin deficiency induces a specific fusiform gyrus lipid-myelin pathology that underlies a distinct visual subtype of autism, suggesting a novel metabolic target for diagnosis and treatment.

β-Amyloid and Glutathione Dysregulation Cooperatively Drive Lipid Peroxidation and Ferroptosis in Neuron-Like Cells

Alzheimer's disease-associated Aβ accumulation synergizes with glutathione depletion to drive neuronal ferroptosis via autophagy-mediated GPX4 suppression, suggesting that preserving redox homeostasis or targeting ferroptotic pathways offers a promising therapeutic strategy.